Table 3 The further anti-tumor therapy following the completion of famitinib or placebo treatment in the full analysis set
Further therapy | Famitinib group [cases (%)] (n = 99) | Placebo group [cases (%)] (n = 55) |
|---|---|---|
Chemotherapy | 21 (21.2) | 6 (10.9) |
Traditional Chinese medicine | 4 (4.0) | 4 (7.3) |
McAb | 0 (0.0) | 7 (12.7) |
Chemotherapy plus McAb | 2 (2.0) | 3 (5.5) |
Cellular immunotherapy | 0 (0.0) | 2 (3.6) |
Cellular immunotherapy plus chemotherapy | 1 (1.0) | 0 (0.0) |
Targeted therapy | 0 (0.0) | 1 (1.8) |
Radiotherapy | 3 (3.0) | 2 (3.6) |
Radiochemotherapy | 1 (1.0) | 1 (1.8) |
Surgery | 2 (2.0) | 1 (1.8) |
Interventional therapy | 2 (2.0) | 0 (0.0) |
Unspecified | 6 (6.1) | 2 (3.6) |